SCHEMBL19732271

SCHEMBL19732271

CN(C)CCN1C(=O)c2cc(N)cc3cc(N)cc(c23)C1=O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 0.80
CYP2D6 P10635 1/20 0.80
POLB P06746 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
CYP1A2 P05177 1/20 0.60
TNNI3 P19429 1/20 0.60
MAPK1 P28482 1/20 0.60
STAT6 P42226 1/20 0.60
TNNT2 P45379 1/20 0.60
TNNC1 P63316 1/20 0.60
HEXA P06865 1/20 0.59
HEXB P07686 1/20 0.59
TERT O14746 2/20 0.53
PABPC1 P11940 2/20 0.51
LCK P06239 2/20 0.49
AHR P35869 2/20 0.49
NR1I2 O75469 1/20 0.49
RAD52 P43351 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amonafide SCHEMBL6255345 0.89 FTO (1.00) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL27226 0.89 FTO (1.00) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL29352008 0.89 FTO (1.00) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL1566668 0.88 FTO (0.97) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL1051955 0.88 FTO (0.97) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL1049714 0.88 FTO (0.97) FTOCYP2D6POLBMEN1KMT2A
SCHEMBL9017071 0.87 FTO (0.71) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL20242315 0.84 FTO (0.88) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL1565520 0.83 FTO (0.86) FTOCYP2D6POLBMEN1KMT2A
Amonafide SCHEMBL9144516 0.83 FTO (0.86) FTOCYP2D6POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11007271-B2 Anticancer drug conjugates Ariel Scientific Innovations Ltd. (IL) 2021-05-18 US disclosed
US-20190224328-A1 ANTICANCER DRUG CONJUGATES Ariel Scientific Innovations Ltd. (IL) 2019-07-25 US disclosed
WO-2017216791-A9 ANTICANCER DRUG CONJUGATES Ariel Scientific Innovations Ltd. (IL) 2018-02-08 WO disclosed
WO-2017216791-A1 ANTICANCER DRUG CONJUGATES Ariel Scientific Innovations Ltd. (IL) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190224328-A1 ANTICANCER DRUG CONJUGATES BCR, MCL1, TP53 FTO 3650/4885CYP2D6 1582/4885POLB 3284/4885
US-11007271-B2 Anticancer drug conjugates BCR, MCL1, TP53 FTO 3650/4885CYP2D6 1582/4885POLB 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.